以氫氧基磷灰石作為載體乘載白芨多醣體作為肌少症的預防用藥

肌少症是一個隨著年齡老化而造成的肌肉質量減少以及肌肉功能衰退之疾病。有鑑於目前的醫療技術在肌少症發病之後並沒有相當有效及無副作用的治療方式，且氫氧基磷灰石為身體中骨骼及牙齒的組成分之一，有著良好的生物相容性及生物可降解性，不僅能夠補充老年人身體中所缺失的鈣質更能透過藥物長期釋放的方式減少所需施打藥物的次數及頻率，降低年長者所受之痛。本實驗以預防勝於治療的初衷作為出發點，先對實驗的大鼠施打以氫氧基磷灰石(Hydroxyapatie , HAp)乘載白芨多醣體(Bletilla striata , BSP)之藥物，再施打從大腸桿菌中所萃取出的脂多醣，誘導類似肌少症所產生的肌肉損傷及發炎反應。觀察實驗組及對照組 (單純施打脂多醣誘導肌肉損傷及發炎反應) 之間的差別，並以肌肉拉力測試、小動物跑步機之肌耐力檢測、血液分析、組織切片及MRI等檢測結果來分析本實驗之藥物是否有達到預防肌肉損傷及抗發炎的效果。根據ISO-10993之標準本實驗所合成之HAp、BSP及HAp-BSP是無生物毒性且有良好生物相容性。經由TGA熱重分析檢測，本實驗所合成之HAp-BSP載藥量約為13%，且BSP揮發溫度落在300 oC與參考文獻中所提及白芨多醣體揮發溫度相同。本實驗成功利用LPS誘導類似肌少症之肌肉損傷及發炎反應，且利用HAp-BSP能成功預防LPS所引發的症狀，證實HAp-BSP有其抗氧化及促進組織增生的效果。

關鍵字

白芨；肌少症；氫氧基磷灰石

並列摘要

Sarcopenia is a disease of muscle mass loss and muscle function decline caused by aging. Because there are no effective and no side effects treatments to treat sarcopenia, and hydroxyapatite is one of the components of bones and teeth in human body, has well biocompatibility and biodegradability. Not only can supplement the body of the lack of calcium in the body but also through the drug long-term Release to reduce the drug injection frequency, mitigate the pain suffered by the elderly. In this study, the starting point is that prevention is better than treatment . Inject HAp─BSP first then inject lipopoly- saccharide extracted from E.coli which is going to induce muscle injury and re- duction muscle mass that are similar to the symptoms of sarcopenia. To observe the difference between the experimental group and the control group (induced by LPS-induced muscle injury and inflammatory reaction), and to analyze the results of muscle tension test, muscle endurance test, blood analysis, HE stain and MRI image to find whether HAp─BSP can prevent muscle injury and anti-inflammatory. According to ISO-10993, HAp, BSP and HAp-BSP prepared in this experiment are biologically toxic and have good biocompatibility. Through the TGA analysis, HAp-BSP drug loading efficiency is about 13%, and the BSP volatilization at 300 oC, which is the same as the re- ference. In this study, we successfully used LPS to induce muscle injury that similar to sarcopenia, and HAp-BSP could prevent the symptoms caused by LPS. It was confirmed that HAp-BSP had its anti-oxidation and promoting tissue capacity.

並列關鍵字

bletilla striata ； sarcopenia ； hydroxyapatite

參考文獻

1. Shyong, Y.J., et al., Mesoporous Hydroxyapatite as Olanzapine Carrier Provides a Long-Acting Effect in Antidepression Treatment. J Med Chem, 2015. 58(21): p. 8463-74.

2. Yu, J., The etiology and exercise implications of sarcopenia in the elderly. International Journal of Nursing Sciences, 2015. 2(2): p. 199-203.

3. Lang, T., et al., Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int, 2010. 21(4): p. 543-59.

4. Bowen, T.S., G. Schuler, and V. Adams, Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle, 2015. 6(3): p. 197-207.

5. Chen, L.K., et al., Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc, 2014. 15(2): p. 95-101.

國際替代計量

以氫氧基磷灰石作為載體乘載白芨多醣體作為肌少症的預防用藥

全文下載

主題瀏覽